I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Akero Therapeutics announced promising results from the 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for treating pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) Akero Therapeutics snapped a two-day losing streak on Tuesday, jumping 24.72 percent to close at $47.57 apiece as investors gobbled up shares following news ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including ...

SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Akero Therapeutics has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -9.96 and a beta of -0.18.

Akero Therapeutics has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics, Inc. has successfully completed its underwritten public offering, selling 6,427,170 shares of common stock at $48.00 per share, including an over-allotment option for an ...